Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP and Ortav Yehudai report beneficial ownership of Camp4 Therapeutics Corp common stock. As of August 3, 2026, they may be deemed to beneficially own 3,790,636 shares of Camp4 common stock, representing 6% of the outstanding shares. All reported shares are held directly by Trails Edge Biotechnology, with Trails Edge Capital as investment manager and Mr. Yehudai exercising voting and investment discretion. Camp4 had 62,753,200 shares outstanding as of the same date, as referenced from its Form S-3.
Key Figures
Beneficial ownership:3,790,636 sharesOwnership percentage:6%Shares outstanding:62,753,200 shares+3 more
6 metrics
Beneficial ownership3,790,636 sharesCamp4 common stock beneficially owned by the filers as of August 3, 2026
Ownership percentage6%Portion of Camp4 outstanding common stock beneficially owned by the filers
Shares outstanding62,753,200 sharesCamp4 common stock issued and outstanding as of August 3, 2026
Sole voting power3,790,636 sharesShares over which each filer reports sole power to vote
Sole dispositive power3,790,636 sharesShares over which each filer reports sole power to dispose
Event dateAugust 3, 2026Date as of which ownership in Camp4 shares is reported
Key Terms
beneficially own, sole voting power, sole dispositive power, Schedule 13G, +1 more
5 terms
beneficially ownfinancial
"each Filer may be deemed to beneficially own an aggregate of 3,790,636 Common Stock"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
sole voting powerfinancial
"Sole Voting Power 3,790,636.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive powerfinancial
"Sole Dispositive Power 3,790,636.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Schedule 13Gregulatory
"Ownership percentages are based on 62,753,200 Shares issued and outstanding as of August 3, 2026, as reported"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
CUSIP Numberfinancial
"CUSIP Number(s): 13463J101"
A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Camp4 Therapeutics Corp (CAMP) does Trails Edge report?
Trails Edge entities report beneficial ownership of 3,790,636 shares of Camp4 Therapeutics common stock, representing 6% of the outstanding shares as of August 3, 2026, all held directly by Trails Edge Biotechnology Master Fund.
Who are the filers in this Schedule 13G related to Camp4 (CAMP)?
The filers are Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai, who serves as Chief Investment Officer of Trails Edge Capital and exercises voting and investment discretion over the reported Camp4 shares.
How many Camp4 (CAMP) shares are outstanding according to this report?
The report states that Camp4 Therapeutics had 62,753,200 shares of common stock issued and outstanding as of August 3, 2026, based on information from the company’s Form S-3 registration statement.
What voting and dispositive power do the filers have over Camp4 (CAMP) shares?
Each filer reports sole voting power and sole dispositive power over 3,790,636 shares of Camp4 common stock, with no shared voting or dispositive power indicated for any of the filers.
What is Ortav Yehudai’s role in relation to the Camp4 (CAMP) holdings?
Ortav Yehudai is the Chief Investment Officer of Trails Edge Capital and exercises voting and investment discretion over the 3,790,636 Camp4 shares, and therefore may be deemed to beneficially own 6% of the outstanding shares as of the event date.
Where are the Trails Edge filers for the Camp4 (CAMP) stake based?
The principal business address for all filers is 3445 Peachtree Road NE, Suite 900, Atlanta, GA 30326, while Camp4 Therapeutics’ principal executive offices are in Cambridge, Massachusetts.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Camp4 Therapeutics Corp
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
13463J101
(CUSIP Number)
08/03/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
13463J101
1
Names of Reporting Persons
Trails Edge Capital Partners, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
3,790,636.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,790,636.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,790,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6 %
12
Type of Reporting Person (See Instructions)
IA, PN
Comment for Type of Reporting Person: See Item 4 for additional information.
SCHEDULE 13G
CUSIP Number(s):
13463J101
1
Names of Reporting Persons
Trails Edge Biotechnology Master Fund, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
3,790,636.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,790,636.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,790,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: See Item 4 for additional information.
SCHEDULE 13G
CUSIP Number(s):
13463J101
1
Names of Reporting Persons
Ortav Yehudai
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
3,790,636.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,790,636.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,790,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: See Item 4 for additional information.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Camp4 Therapeutics Corp
(b)
Address of issuer's principal executive offices:
One Kendall Square, Building 1400 West, 3rd Floor. Cambridge, MA 02139.
Item 2.
(a)
Name of person filing:
This report on Schedule 13G is being filed by Trails Edge Capital Partners, LP, a Delaware limited partnership ("Trails Edge Capital"), Trails Edge Biotechnology Master Fund, LP, a Cayman Islands limited partnership ("Trails Edge Biotechnology"), and Ortav Yehudai ("Mr. Yehudai"). Trails Edge Capital is the investment manager to Trails Edge Biotechnology, and Mr. Yehudai is the Chief Investment Officer of Trails Edge Capital. Each of Trails Edge Capital, Trails Edge Biotechnology and Mr. Yehudai are referred to individually as a "Filer" and collectively as the "Filers".
(b)
Address or principal business office or, if none, residence:
The address for each Filer is 3445 Peachtree Road NE, Suite 900, Atlanta, GA 30326.
(c)
Citizenship:
See Item 4 of the cover page of each Filer.
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP Number(s):
13463J101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of August 3, 2026 (the "Event Date"), each Filer may be deemed to beneficially own an aggregate of 3,790,636 Common Stock, $0.0001 par value per share (the "Shares"), of Camp4 Therapeutics Corporation (the "Issuer"). The 3,790,636 Shares reported as beneficially owned on this Schedule 13G by each Filer consist of 3,790,636 Shares held directly by Trails Edge Biotechnology. As a result, Trails Edge Biotechnology beneficially owns approximately 6% of the outstanding Shares of the Issuer as of the Event Date. Trails Edge Capital, as the investment manager to Trails Edge Biotechnology, may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own approximately 6% of the outstanding Shares of the Issuer as of the Event Date.
Ownership percentages are based on 62,753,200 Shares issued and outstanding as of August 3, 2026, as reported by the Issuer in its Registration Statement on Form S-3, filed with the Securities and Exchange Commission on August 6, 2026.
(b)
Percent of class:
6%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
3,790,636.00
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
3,790,636.00
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Trails Edge Capital Partners, LP
Signature:
/s/ Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai
Name/Title:
Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC
Date:
08/10/2026
Trails Edge Biotechnology Master Fund, LP
Signature:
/s/ Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai
